In glucocorticoid-dependent polymyalgia rheumatica, tocilizumab improved a composite clinical outcome at 24 wk.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 36592464.
- Also identified by DOI 10.7326/J22-0107.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. <b>Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial.</b> JAMA. 2022;328:1053-62. 36125471.
Medical subject headings
- Giant Cell Arteritis
- Polymyalgia Rheumatica